Evidence Synthesis in Pulmonary Arterial Hypertension: a Systematic Review and Critical Appraisal

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2020 Jul 30

PMID 32723397

Citations 3

Authors

Max Schlueter

Amelie Beaudet

Evan Davies

Binu Gurung

Andreas Karabis

Affiliations

Soon will be listed here.

Abstract

Background: The clinical landscape of pulmonary arterial hypertension (PAH) has evolved in terms of disease definition and classification, trial designs, available therapies and treatment strategies as well as clinical guidelines. This study critically appraises published evidence synthesis studies, i.e. meta-analyses (MA) and network-meta-analyses (NMA), to better understand their quality, validity and discuss the impact of the findings from these studies on current decision-making in PAH.

Methods: A systematic literature review to identify MA/NMA studies considering approved and available therapies for treatment of PAH was conducted. Embase, Medline and the Cochrane's Database of Systematic Reviews were searched from database inception to April 22, 2020, supplemented by searches in health technology assessment websites. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) checklist covering six domains (relevance, credibility, analysis, reporting quality and transparency, interpretation and conflict of interest) was selected for appraisal of the included MA/NMA studies.

Results: Fifty-two full publications (36 MAs, 15 NMAs, and 1 MA/NMA) in PAH met the inclusion criteria. The majority of studies were of low quality, with none of the studies being scored as 'strong' across all checklist domains. Key limitations included the lack of a clearly defined, relevant decision problem, shortcomings in assessing and addressing between-study heterogeneity, and an incomplete or misleading interpretation of results.

Conclusions: This is the first critical appraisal of published MA/NMA studies in PAH, suggesting low quality and validity of published evidence synthesis studies in this therapeutic area. Besides the need for direct treatment comparisons assessed in long-term randomized controlled trials, future efforts in evidence synthesis in PAH should improve analysis quality and scrutiny in order to meaningfully address challenges arising from an evolving therapeutic landscape.

Citing Articles

Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis.

Moutchia J, McClelland R, Al-Naamani N, Appleby D, Holmes J, Minhas J Eur Heart J. 2024; 45(21):1937-1952.

PMID: 38416633 PMC: 11143388. DOI: 10.1093/eurheartj/ehae049.

Risk Factors for Pulmonary Arterial Hypertension in Patients With Systemic Lupus Erythematosus: A Systematic Review and Expert Consensus.

Atsumi T, Bae S, Gu H, Huang W, Li M, Nikpour M ACR Open Rheumatol. 2023; 5(12):663-676.

PMID: 37794618 PMC: 10716809. DOI: 10.1002/acr2.11611.

Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis.

Pitre T, Su J, Cui S, Scanlan R, Chiang C, Husnudinov R Eur Respir Rev. 2022; 31(165).

PMID: 35948391 PMC: 9724821. DOI: 10.1183/16000617.0036-2022.

References

Jain S, Khera R, Girotra S, Badesch D, Wang Z, Murad M . Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis. Chest. 2016; 151(1):90-105. PMC: 5310124. DOI: 10.1016/j.chest.2016.08.1461. View

Cipriani A, Higgins J, Geddes J, Salanti G . Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013; 159(2):130-7. DOI: 10.7326/0003-4819-159-2-201307160-00008. View

Thom H, Capkun G, Cerulli A, Nixon R, Howard L . Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension. BMC Med Res Methodol. 2015; 15:34. PMC: 4403724. DOI: 10.1186/s12874-015-0007-0. View

He B, Zhang F, Li X, Tang C, Lin G, Du J . Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J. 2010; 74(7):1458-64. DOI: 10.1253/circj.cj-09-0971. View

Zhang H, Li X, Huang J, Li H, Su Z, Wang J . Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis. Medicine (Baltimore). 2016; 95(4):e2575. PMC: 5291571. DOI: 10.1097/MD.0000000000002575. View

Khouri C, Lepelley M, Roustit M, Montastruc F, Humbert M, Cracowski J . Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database. Chest. 2017; 154(1):136-147. DOI: 10.1016/j.chest.2017.12.008. View

Pan J, Lei L, Zhao C . Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Clin Exp Rheumatol. 2018; 36(6):1095-1102. View

Badiani B, Messori A . Targeted Treatments for Pulmonary Arterial Hypertension: Interpreting Outcomes by Network Meta-analysis. Heart Lung Circ. 2015; 25(1):46-52. DOI: 10.1016/j.hlc.2015.05.020. View

McLaughlin V, Badesch D, Delcroix M, Fleming T, Gaine S, Galie N . End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S97-S107. DOI: 10.1016/j.jacc.2009.04.007. View

10.

Savarese G, Paolillo S, Costanzo P, DAmore C, Cecere M, Losco T . Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012; 60(13):1192-201. DOI: 10.1016/j.jacc.2012.01.083. View

11.

Pan Y, Hu C, Chen P, Gu Y, Qiao Q, Pan L . Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2016; 73(3):267-278. DOI: 10.1007/s00228-016-2171-5. View

12.

Singh T, Rohit M, Grover A, Malhotra S, Vijayvergiya R . A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006; 151(4):851.e1-5. DOI: 10.1016/j.ahj.2005.09.006. View

13.

Jansen J, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N . Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011; 14(4):417-28. DOI: 10.1016/j.jval.2011.04.002. View

14.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

15.

Sitbon O, Channick R, Chin K, Frey A, Gaine S, Galie N . Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26):2522-33. DOI: 10.1056/NEJMoa1503184. View

16.

Duo-Ji M, Long Z . Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis. Int J Cardiol. 2017; 234:90-98. DOI: 10.1016/j.ijcard.2016.12.092. View

17.

Macchia A, Marchioli R, Tognoni G, Scarano M, Marfisi R, Tavazzi L . Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J. 2010; 159(2):245-57. DOI: 10.1016/j.ahj.2009.11.028. View

18.

Barst R, Rubin L, Long W, McGoon M, Rich S, Badesch D . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334(5):296-301. DOI: 10.1056/NEJM199602013340504. View

19.

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

20.

Vizza C, Badagliacca R, Messick C, Rao Y, Nelsen A, Benza R . The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis. Int J Cardiol. 2017; 254:299-301. DOI: 10.1016/j.ijcard.2017.12.016. View